文献速递前列腺癌

血液液态活检在前列腺癌临床决策中的定量与定性分析

Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer.
PubMed 文献 · Eur Urol · 2021-01-07

本文系统综述了血液液态活检(CTC、ctDNA、EVs)在前列腺癌临床决策中的价值。液态活检可动态刻画肿瘤基因组、表观基因组、转录组和蛋白质组演变,在局限期和晚期前列腺癌中均展现诊断、预后和疗效预测潜力,但临床实施前需标准化和验证。

要点

  • 血液液态活检可微创动态监测前列腺癌分子特征演变。
  • 晚期转移性去势抵抗性前列腺癌中CTC和ctDNA产量显著更高。
  • 临床应用前需完成检测标准化及分析/临床验证。

核心结论

  • 血液液态活检可作为前列腺癌预后、预测和疗效反应生物标志物来源。
  • 多数临床应用在晚期转移性设置中开发,因CTC和ctDNA产量显著更高。
  • 临床实施前需标准化检测并完成分析/临床验证。

研究设计与样本

  • 对PubMed/MEDLINE进行系统综述,检索前列腺癌血液CTC、ctDNA和EVs相关文献。

主要发现

  • 液态活检可随时间刻画肿瘤动态,揭示随进展演变的基因组、表观基因组、转录组和蛋白质组特征。
  • 液态活检检测涵盖CTC、ctDNA或EVs中可检测的DNA、RNA和蛋白质分析。
  • 血液液态活检在局限期肿瘤(诊断特征、风险分层、疾病监测)和晚期疾病(反应/耐药生物标志物、预后标志物)中展现前景。

临床怎么用

  • 液态活检可用于前列腺癌的诊断辅助、风险分层、疾病监测及晚期疗效/耐药评估。
  • 在晚期转移性前列腺癌中CTC和ctDNA产量更高,检测可行性更优。

局限性

  • 检测标准化及分析/临床验证不足,限制临床实施。
  • 多数临床应用证据集中在晚期转移性设置,局限期应用证据相对有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Genomic stratification can impact prostate cancer (PC) care through diagnostic, prognostic, and predictive biomarkers that aid in clinical decision-making. The temporal and spatial genomic heterogeneity of PC together with the challenges of acquiring metastatic tissue biopsies hinder implementation of tissue-based molecular profiling in routine clinical practice. Blood-based liquid biopsies are an attractive, minimally invasive alternative. OBJECTIVE: To review the clinical value of blood-based liquid biopsy assays in PC and identify potential applications to accelerate the development of precision medicine. EVIDENCE ACQUISITION: A systematic review of PubMed/MEDLINE was performed to identify relevant literature on blood-based circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs) in PC. EVIDENCE SYNTHESIS: Liquid biopsy has emerged as a practical tool to profile tumor dynamics over time, elucidating features that evolve (genome, epigenome, transcriptome, and proteome) with tumor progression. Liquid biopsy tests encompass analysis of DNA, RNA, and proteins that can be detected in CTCs, ctDNA, or EVs. Blood-based liquid biopsies have demonstrated promise in the context of localized tumors (diagnostic signatures, risk stratification, and disease monitoring) and advanced disease (response/resistance biomarkers and prognostic markers). CONCLUSIONS: Liquid biopsies have value as a source of prognostic, predictive, and response biomarkers in PC. Most clinical applications have been developed in the advanced metastatic setting, where CTC and ctDNA yields are significantly higher. However, standardization of assays and analytical/clinical validation is necessary prior to clinical implementation. PATIENT SUMMARY: Traces of tumors can be isolated from blood samples from patients with prostate cancer either as whole cells or as DNA fragments. These traces provide information on tumor features. These minimally invasive tests can guide diagnosis and treatment selection.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Casanova-Salas I, Athie A, Boutros PC, et al. Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. Eur Urol. 2021. PMID: 33422353. doi:10.1016/j.eururo.2020.12.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。